Open an account

SAB Biotherapeutics

SABS · NASDAQ

$2.88+$0.28 (+10.77%)TodayMarket closed ·
Prev close $2.60

About SABS

SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company, which engages in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. The company is headquartered in Miami Beach, Florida and currently employs 86 full-time employees. The company went IPO on 2021-01-12. The firm is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.

Employees
86
Headquarters
Miami Beach, Florida
Listed
Jan 12, 2021
Sector
Health Care
Industry
Biotechnology
Website
sab.bio

SABS key statistics

Market cap
262.04M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
758.17K
Volume
814.54K
Open price
$2.59
High today
$2.93
Low today
$2.55
52 Week high
$5.15
52 Week low
$2.44

SAB Biotherapeutics (SABS) at a glance

SAB Biotherapeutics (SABS) last traded at $2.88, with a market cap of 262.04M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.55 and $2.93. The current price is 12.8% above the day's low and 1.7% below its high.

Volume so far is 814.54K shares, in line with the average of 758.17K shares a day.

Over the past year SAB Biotherapeutics has ranged from $2.44 to $5.15, and now sits 16% of the way up that range.

SAB Biotherapeutics met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.28 per share against an estimate of -$0.2952.

The average analyst price target is $11.87, 312.1% above the current price, from 9 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 9 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 13 analystsAvg $11.87
Low
$6.06
Now
$2.88
High
$16.80

SABS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 40.9% on average.

  1. Q3 FY24: reported -$1.12 per share against an estimate of -$1.11
  2. Q4 FY24: reported -$1.23 per share against an estimate of -$1.19
  3. Q1 FY25: reported -$0.56 per share against an estimate of -$1.05
  4. Q2 FY25: reported -$1.09 per share against an estimate of -$0.8119
  5. Q3 FY25: reported -$0.15 per share against an estimate of -$0.5161
  6. Q4 FY25: reported -$0.35 per share against an estimate of -$0.2027
  7. Q1 FY26: reported -$0.35 per share against an estimate of -$0.2329
  8. Q2 FY26: reported -$0.28 per share against an estimate of -$0.2952

SABS news

  • Press releaseGlobe Newswire

    SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights

  • Press releaseGlobe Newswire

    SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • Press releaseGlobe Newswire

    SAB BIO to Participate in Upcoming Investor Conferences

  • Avi Kapoor

    Gold Gains 1%; Boeing Shares Rise Following Q4 Results

  • Avi Kapoor

    Nasdaq Surges More Than 300 Points; Lockheed Martin Shares Dip After Q4 Results

  • Avi Kapoor

    Dow Gains Over 50 Points; General Motors Posts Upbeat Earnings

Similar companies

Companies in the same industry as SAB Biotherapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.